Novel Adjuvants for Peptide-Based Melanoma Vaccines
Study Details
Study Description
Brief Summary
This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
In the Phase I/II trial, patients with resected stages III and IV melanoma who have been rendered free of disease, but are at high risk of relapse, are treated with peptides/IFA at a dose of 0.5 mg each peptide plus CTLA-4 antibody given intravenously, 3 mg/kg, after each vaccination. In the Phase II randomized study, patients are treated with the melanoma peptide vaccine alone, with CTLA-4 antibody, or with CTLA-4 antibody combined with IL-12 at 30 ng/kg with alum. The peptides are tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35 (27L) which are emulsified with IFA. The dosing schedule for both trials are at 1, 2, 3, 4, 5, and 6 months; then at 9 and 12 for a total of 8 vaccinations.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion criteria:
-
Diagnosis of stage III or IV cutaneous, mucosal, or ocular melanoma
-
Completely resected disease or disease-free
-
HLA-A2.1 positive
-
Tumor tissue available for immunohistochemical analysis and staining positive for at least 1 of the specified antigens
-
At least 1 month since prior therapy for cancer, including radiotherapy and adjuvant therapy
-
WBC count at least 3,000/mm3
-
Granulocyte count at least 1,500/mm3
-
Platelet count at least 100,000/mm3
-
Hemoglobin at least 9.0 gm/dL
-
Creatinine no greater than 2.0 mg/dL
-
Bilirubin no greater than 2.0 mg/dL
-
SGOT/SGPT no greater than 2.5 times upper limit of normal
-
ECOG performance status 0-1
-
Have failed alpha-interferons (patients with resected stage III disease)
Exclusion criteria:
-
Prior treatment with tyrosinase: 368-376(370D), gp100:209-217(210M), and MART-1:26-35(27L) peptides
-
Steroid therapy or other immunosuppressive medication requirement
-
Major systemic infections (e.g., pneumonia or sepsis)
-
Coagulation or bleeding disorders
-
Major medical illnesses of the gastrointestinal, cardiovascular, or respiratory systems
-
Allergic reaction to Montanide ISA 51 (incomplete Freund's adjuvant)
-
History of uveitis or autoimmune inflammatory eye disease
-
Other active autoimmune disease
-
Positive for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody
-
Pregnant or nursing
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Universtiy of Southern California/Kenneth Norris, Jr. Comprehensive Cancer Center | Los Angeles | California | United States | 90089 |
Sponsors and Collaborators
- University of Southern California
Investigators
- Principal Investigator: Jeffrey S. Weber, M.D., Ph.D., University of Southern California/Norris Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FD-R-1975-01
- 10M-00-4;
- FD-R-001975-01